NEL HOME, Newsletter
CONTENTS Vol.24 Nos.1/2 Feb-Apr 2003
VOL.22, 2001
VOL.21, 2000
VOL.20, 1999
VOL.19, 1998
VOL.18, 1997
PREVIEW coming

including Psychoneuroimmunology, Neuropsychopharmacology,
Reproductive Medicine, Chronobiology
and Human Ethology, ISSN 0172–780X

NEL Vol.24 No.1/2, Feb-Apr 2003


Endocrine effects of apomorphine in cancer

2003; 24:5053
pii: NEL241203A03
PMID: 12743532

[Read pdf 135kb]

Buy PDF article
Check Out


Psychoncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients

Paolo Lissoni, Fabio Malugani, Vittorio Manganini, Antonio Ardizzoia, Gianstefano Gardani, Erio Bartolacelli, Giusy Messina & Gabriele Tancini

1. Division of Radiation Oncology, S.Gerardo Hospital, Monza, Milan, Italy;
2. Division of Urology, S.Gerardo Hospital, Monza, Milan, Italy;
3. Psychoncology Service, S.Gerardo Hospital, Monza, Milan, Italy.

Submitted: October 10, 2002 Accepted: November 11, 2002

Key words:
puberty, serotonin, GABA, catecholamines



OBJECTIVES: The clinical approach of the Psychoncology is generally limited to the investigation of the only psychological status of cancer patients, without taking into consideration the well demonstrated cancer progression-related psychoneuroendocrine alterations, namely consisting of a progressive decline in the pineal endocrine function and an anomalous activity of brain opioid system. The endocrine response to apomorphine, a dopaminergic agent, has been proven to reflect the dopaminergic sensitivity, which would be involved at least in part in pleasure-related neurochemical mechanisms. The present study was performed to analyze the endocrine response to apomorphine in metastatic cancer patients, as a preliminary approach to the investigation of pleasure-related neuroendocrine mechanisms in human neoplasms.

MATERIALS & METHODS: The study included 10 metastatic cancer male patients and 6 male volunteers as a control group. Apomorphine was given orally at 0.01 mg/kg body weight in the morning, and venous blood samples were collected before, and at 20, 60 and 120 minutes after apomorphine administration. The endocrine analysis consisted of the measurement of serum levels of GH, PRL and cortisol. RESULTS: All cancer patients presented alterations involving one or more endocrine responses to apomorphine. GH and cortisol mean levels after apomorphine were significantly higher in controls than in cancer patients, whereas no substantial difference occurred in those of PRL.

CONCLUSIONS: This preliminary study, by showing an altered endocrine response to apomorphine in metastatic cancer patients, would suggest that cancer progression may be associated with an altered dopaminergic sensitivity. Because of the involvement of the dopaminergic system in pleasure-related neurochemical mechanisms, this finding would demonstrated that the decline in the perception of pleasure with cancer progression may depend not only on psychological factors, but also, at least in part, on psychochemical alterations occurring during the clinical course of the neoplastic disease.

Copyright  Neuroendocrinology Letters 2003
Society of Integrated Sciences
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief.
The latest statistics from the www.nel.edu